Atria Investments Inc Has $413,000 Stock Holdings in Azenta, Inc. (NASDAQ:AZTA)

Atria Investments Inc lowered its stake in shares of Azenta, Inc. (NASDAQ:AZTA) by 11.0% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,251 shares of the company’s stock after selling 1,019 shares during the period. Atria Investments Inc’s holdings in Azenta were worth $413,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. State Street Corp grew its stake in shares of Azenta by 0.4% in the 3rd quarter. State Street Corp now owns 1,686,993 shares of the company’s stock valued at $81,718,000 after buying an additional 6,398 shares in the last quarter. Conestoga Capital Advisors LLC raised its position in Azenta by 65.0% during the fourth quarter. Conestoga Capital Advisors LLC now owns 1,577,881 shares of the company’s stock valued at $78,894,000 after acquiring an additional 621,830 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Azenta by 1.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,317,385 shares of the company’s stock valued at $65,922,000 after acquiring an additional 18,529 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Azenta by 11.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 461,603 shares of the company’s stock worth $23,080,000 after purchasing an additional 48,064 shares in the last quarter. Finally, Systematic Financial Management LP boosted its stake in shares of Azenta by 8.7% during the 3rd quarter. Systematic Financial Management LP now owns 434,597 shares of the company’s stock worth $21,052,000 after acquiring an additional 34,849 shares in the last quarter. 99.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on AZTA shares. Evercore ISI increased their price target on shares of Azenta from $50.00 to $52.00 and gave the company an “in-line” rating in a report on Thursday, February 6th. TD Cowen raised shares of Azenta to a “hold” rating in a research note on Thursday, February 27th. Needham & Company LLC increased their price target on shares of Azenta from $55.00 to $59.00 and gave the stock a “buy” rating in a research report on Thursday, February 6th. Finally, Stephens reaffirmed an “overweight” rating and set a $60.00 price objective on shares of Azenta in a report on Thursday, January 2nd. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $58.75.

Azenta Trading Up 0.7 %

AZTA stock opened at $36.80 on Monday. Azenta, Inc. has a 1-year low of $35.90 and a 1-year high of $63.58. The business’s 50-day moving average price is $48.16 and its two-hundred day moving average price is $47.03. The firm has a market cap of $1.68 billion, a PE ratio of -12.35 and a beta of 1.52.

Azenta (NASDAQ:AZTA) last released its earnings results on Wednesday, February 5th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.05 by $0.03. Azenta had a positive return on equity of 1.25% and a negative net margin of 24.91%. On average, analysts forecast that Azenta, Inc. will post 0.53 earnings per share for the current year.

Azenta Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.